NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
Volume
N/A
Average Volume
1.61 million shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FTSV stock logo

About Forty Seven Stock (NASDAQ:FTSV)

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

FTSV Stock News Headlines

[URGENT] DO NOT Touch These AI Stocks!
Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?
49ers sign veteran tight end
Formula Systems (1985) Ltd ADR FORTY
[URGENT] DO NOT Touch These AI Stocks!
Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?
Week one: seven-day detox
Meet our Forty Under 40 winners
FTSV_old Historical Data
See More Headlines
Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2019
Today
5/13/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FTSV
CIK
N/A
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-87,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.68 million
Book Value
$7.52 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
0.40
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Mark A. McCamish (Age 66)
    Pres, CEO & Director
  • Dr. Craig S. Gibbs (Age 56)
    Chief Bus. Officer
  • Dr. Chris H. Takimoto M.D. (Age 60)
    Ph.D., Chief Medical Officer
  • Mr. Mark Chao
    Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer
    Founder and VP of Research & Early Devel.

FTSV Stock Analysis - Frequently Asked Questions

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million.

What other stocks do shareholders of Forty Seven own?
When did Forty Seven IPO?

Forty Seven (FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

This page (NASDAQ:FTSV) was last updated on 5/13/2024 by MarketBeat.com Staff

From Our Partners